Title: Quantitative descriptions of structure-function relationships of glycoSHIELD of coronavirus spike proteins
Dr. Danny Hsu is a Research Fellow at the Institute of Biological Chemistry, Academia Sinica. During his doctorate study at Utrecht University, the Netherlands, he determined the atomic structure of a lantibiotic, nisin, in complex with Gram-positive bacterial cell wall precursor, Lipid II. He coined the term "pyrophosphate case" to explain how nisin targets Lipid II to achieve its antimicrobial activity, providing a blueprint for future antibiotics developments. During his postdoctoral research at the University of Cambridge, UK, Danny demonstrated the proof of concept of using solution-state NMR spectroscopy to investigate the co-translational folding of nascent polypeptide chains on the ribosome. His earlier independent research focused on the folding mechanisms and functional implications of topologically knotted proteins. He currently focuses on developing an integrated biophysics and structural biology platform, including cryo-electron microscopy, mass spectrometry, and molecular modeling, to investigate the structure-activity relationship (SAR) of glycoproteins, and coronavirus spike proteins, in particular, and how mutations impact on the SAR in the context of glycosylation.
Title: The gel-forming mucins protecting our intestinal and respiratory tracts are densely glycosylated polymeric proteins
Gunnar C. Hansson, M.D., Ph.D. is a Professor in University of Gothenburg, Sweden. He has been working on mucus, mucins, and mucin glycans his whole career, focusing on the gastrointestinal and respiratory tracts. He has been part of and at the leading edge of developing molecular understanding of mucins over the last 30 years with a focus on their biosynthesis and structure. He and his team discovered that an attached colon mucus layer impenetrable to bacteria separates commensal bacteria from the host and that the chronically diseased lungs are covered with a similar type of mucus. They have studied and discovered that goblet cells making the mucus are more specialized and diverse than previously appreciated. The studied structural variability of glycans on the mucins and their mucin domains are important for commensal bacteria selection and bacterial utilization as a nutritional source. He has founded the Mucin Biology Groups constellation with a total of seven PIs working in the area at the University of Gothenburg (www.medkem.gu.se/mucinbiology).
Title: Regulation of the Biosynthesis of Glycopeptidolipids in Mycobacterium Abscessus
Dr. Guérardel is a senior researcher for CNRS (Lille University, France) and an Invited Professor at iGCORE (Gifu University, Japan). His research focuses on the structure-to-function relationships of complex carbohydrates, from microorganisms to higher eukaryotes, mostly in the context of host-pathogen interaction. His main objective is to understand how the glycans from both host and pathogen fine-tune the infectious process and how they may be used as diagnosis or therapeutic tools, with a keen interest in mycobacterial, fungus, and viral infections. To reach this goal, Dr. Guérardel integrates a wide range of scientific approaches, including synthetic chemistry, structural analysis using NMR spectroscopy and mass spectrometry, structural biology of proteins, and enzymology.
Title: Making weak antigens strong: exploiting bacterial outer membrane vesicles for delivering glycans to the immune system
Professor Matthew P. DeLisa is the William L. Lewis Professor of Engineering in the School of Chemical and Biomolecular Engineering at Cornell University. His research focuses on understanding and controlling the molecular mechanisms underlying protein biogenesis--folding and assembly, membrane translocation, and post-translational modifications--in the complex environment of a living cell. He received a B.S. in Chemical Engineering from the University of Connecticut in 1996; a Ph.D. in Chemical Engineering from the University of Maryland in 2001; and postdoctoral work at the University of Texas-Austin, Department of Chemical Engineering. DeLisa joined the Department of Chemical and Biomolecular Engineering at Cornell University in 2003. He has also served as a Gastprofessur at the Swiss Federal Institute of Technology (ETH Zürich) in the Institut für Mikrobiologie. He has garnered a number of honors and awards, including most recently the Biotechnology Progress Award for Excellence in Biological Engineering Publication, and was named the to the inaugural “Life Sciences Power 50” by City & State New York. He is an elected fellow of the American Institute for Medical and Biological Engineering, the American Academy of Microbiology, and the American Association for the Advancement of Science. In recent years, he has served on the IDA/DARPA Defense Science Study Group and the National Academies Committee on Innovative Technologies to Advance Pharmaceutical Manufacturing.
Title: A functional study of O-GlcNAcylation on RNA binding protein RBM14
Professor Won Ho Yang received his Ph.D. from Yonsei University, Seoul, Korea, in 2007. After postdoctoral work in the laboratory of Professor Jamey Marth at the UC Santa Barbara, he joined the Department of Systems Biology, Glycosylation Network Research Center, at Yonsei University as an Assistant Professor in 2019. His research interest is understanding the function of protein glycosylation in normal physiology and the pathogenesis of the disease.
Chang Gung Memorial Hospital and University, Taiwan
Title: Cancer immunotherapy targeting glycosphingolipids (GSLs)
Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics.
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.
Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: The human gut microbiota-plant cell wall nexus
Dr. Harry Brumer is a Professor in the Michael Smith Laboratories and Department of Chemistry, and an Associate Member of the Department of Botany and the Department of Biochemistry and Molecular Biology, at the University of British Columbia.
Dr. Brumer’s research interests include the discovery, functional and structural characterization, and biotechnological applications of carbohydrate-active enzymes and carbohydrate-binding proteins. Through close collaboration with geneticists and structural biologists, research in the Brumer group seeks to bring molecular-level insight into the biological processes underpinning carbon flux in ecosystems ranging from the forest to the human gut.
Title: From mucin-type O-glycans to bacterial polysaccharides
Inka Brockhausen received her Ph.D. in Biochemistry at the University of Toronto, Canada. At Toronto’s Hospital for Sick Children, she studied both structures and biosynthesis of O-and N-glycans and discovered a number of novel enzymes in the O- and N-glycosylation pathways. As an associate professor at the University of Toronto, her research interest focused on structural and enzymatic glycosylation abnormalities in cancer and cystic fibrosis. Further studies on the link between glycosylation changes in arthritis and inflammatory conditions were carried out at Queen’s University, Kingston, Canada. A major interest became the discovery of novel glycosyltransferases in bacteria, in collaboration with synthetic chemists, e.g., Walter Szarek, Ole Hindsgaul, Vladimir Torgov, and others that were instrumental in the synthesis of natural substrate analogs. Glycosylation inhibitors were developed that could alter the biological properties of cells or could be anti-bacterial compounds. Current directions in the Brockhausen lab at the Department of Biomedical and Molecular Sciences aim to understand polysaccharide synthesis in bacteria and fungi and the mechanisms of enzymes involved in carbohydrate metabolism. Brockhausen also has a keen interest in protein aggregation in neurodegeneration and is a member of the Centre for Neuroscience Studies.
Title: New Insights about the Glycan Ligands of Siglecs and their Ability to Control Immune Cells
The primary focus of Dr. Matthew Macauley’s laboratory is the immunomodulatory sialic acid-binding Siglec family of receptors. His group develops innovative approaches to probe Siglec-glycan interactions on cells and tissues and use new insights about the biological ligands of Siglecs to test hypotheses about the roles of Siglecs in controlling immune cell function.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.